ClinicalTrials.gg
CompletedNCT00109122Updated Mar 15, 2017

Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

A Phase 2 interventional study of zoster vaccine live (Oka/Merck) and Comparator: placebo (unspecified) in Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
13th of 29
180 · median 160
Started
2001
the only one that year
Phase 2
5 of 29
none open now
Registered
1st of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 13th largest by enrollment, is the only one that started in 2001, is one of 5 in phase 2, and was the 1st registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).

Read the detailed description

The duration of treatment is 12 weeks.

03

Conditions studied

  • Shingles

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who are at least 60 years of age with a history of varicella (shingles)
  • Females must have been .

Exclusion criteria

Exclusion Criteria:

  • Subjects who did not previously participate in the main study of this protocol.
  • Subject had shingles since their 6 month follow-up visit in main phase of study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Interventions

  • Biologicalzoster vaccine live (Oka/Merck)

    Drug page: Chickenpox Vaccine

    Also known as: V211

  • BiologicalComparator: placebo (unspecified)
06

What researchers measure

Primary outcomes

  1. VZV ELISPOT response ~6 weeks after 1 and 2 doses

    Time frame: 6 weeks after 1 and 2 doses

Secondary outcomes

  1. To assess the safety and tolerability of the zoster vaccine. To evaluate the long-term persistence of the VZV-specific cell mediate immunity and the VZV-specific antibody response at 1 through 3 years after 2 doses of vaccine or placebo

    Time frame: 1 through 3 years after vaccination

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schodel FP, Annunziato PW, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >/=60 years of age. Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7. PubMed 22154769 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Feb 2003 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2005
First posted
Apr 25, 2005
Start
Nov 2001
Primary completionActual
Feb 2003
CompletionActual
Jul 2006
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00109122
Responsible party
Sponsor
First posted
Apr 25, 2005
Start date
Nov 2001
Primary completion
Feb 2003
Completion
Jul 2006
Last update
Mar 15, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion